Kenneth Galbraith is recorded as CFO at Zymeworks Inc. (ZYME) since March 31, 2024 and CEO at Zymeworks Inc. (ZYME). The newest filing on record that lists Kenneth Galbraith as CEO at Zymeworks Inc. (ZYME) is dated October 26, 2026. Zymeworks Inc. reported in an 8-K filed January 12, 2026 that Kenneth Galbraith was appointed interim Chief Financial Officer, effective January 9, 2026. Zymeworks Inc. reported in an 8-K filed September 3, 2024 that Kenneth Galbraith resigned as interim Chief Financial Officer and as principal financial officer and principal accounting officer, effective September 1, 2024. Zymeworks Inc. reported in an 8-K filed July 25, 2024 that Kenneth Galbraith resigned as interim Chief Financial Officer, effective September 1, 2024. Equibles holds 5 filed executive changes naming Kenneth Galbraith; each is listed under recent activity with its source filing. The proxy statement of Zymeworks Inc. reports total compensation of $6,613,180 for Kenneth Galbraith in fiscal 2025, including a base salary of $656,763. Disclosed compensation is on record for 4 fiscal years. Kenneth Galbraith has spoken on 17 earnings calls and 1 other investor event across 1 company, most recently for Zymeworks Inc. on September 28, 2026. Zymeworks Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Zymeworks Inc. includes Ali Tehrani (CEO), Kristin Stafford (CFO), Leone Patterson (CFO) and 7 others.
“In connection with Ms. Patterson's removal, effective January 9, 2026, the Board appointed Mr. Kenneth Galbraith, the Company's current Chair of the Board, President and Chief Executive Officer, as the Company's interim Chief Financial Officer.”
Zymeworks Inc. Form 8-K, filed January 12, 2026
· Read the filing
“On August 30, 2024, Mr. Kenneth Galbraith resigned from the positions of interim Chief Financial Officer and as principal financial officer and principal accounting officer of the Company, effective as of the Start Date.”
Zymeworks Inc. Form 8-K, filed September 3, 2024
· Read the filing
Kenneth Galbraith on recent calls
“I'll ask Scott to provide a general I want to answer. Obviously, we won't be able to send any specific until the third quarter is reported by us in November, but I'll see if Scott has any general comments to address your question.”
“First, for those on the call, I hope you and your families are all safe and well, wherever you are joining the call from today. I'd like to begin by recognizing the results of the FACE-Horizon GAO1 trial.”
“Over the last 2 years, we've redefined what this company can achieve by combining R&D innovation, smart partnerships, and disciplined capital allocation to help deliver potential best-in-class therapies while helping to grow shareholder value.”
“As we move through the remainder of 2025, there's no question that capital markets continue to reward clarity, capital discipline and real progress towards durable value.”
